Applicant, as named in the Orange Book

Rigel Pharms

Next listed expiry: Tavalisse on 27 Jul 2032. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Tavalisse · 2 strengths fostamatinib disodium	fostamatinib disodium	209299	27 Jul 2032	patent
Veppanu · 2 strengths vepdegestrant	vepdegestrant	219835	30 Jan 2038	patent
Rezlidhia olutasidenib	olutasidenib	215814	12 Nov 2039	patent
Gavreto pralsetinib	pralsetinib	213721	19 Apr 2043	patent